Ascendiant Capital Markets lifts IGC Pharma price target to $5.5

IGC Pharma, Inc.

IGC Pharma, Inc.

IGC

0.00
  • Ascendiant Capital Markets raised its price target on IGC Pharma to USD 5.5 per share, citing clinical progress.
  • Research report flagged 2026 clinical data and trial execution as potential stock catalysts.
  • Lead program IGC-AD1 is in the Phase 2 CALMA trial for agitation associated with Alzheimer’s disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606090830ACCESSWRNAPR_____1174370) on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.